Rep. Rob Nosse

Extends sunset for tax credit for closure of manufactured dwelling park. Extends sunset for exemption from income or corporate excise taxes of capital gains from sale of manufactured dwelling park to certain entities. Provides that tax credit for closure of manufactured dwelling park may be claimed by tenant based on termination of agreement by landlord or termination of agreement due to exercise of eminent domain. Applies to tax years beginning on or after January 1, 2017. Takes effect on 91st day following adjournment sine die.

Prohibits transplant center from recommending that potential anatomical gift recipient who is medical marijuana patient be removed from list of potential recipients exclusively based on positive result of drug test for marijuana use.

Requires pharmaceutical manufacturers to report to Department of Consumer and Business Services total cost of patient assistance programs and information on financial assistance provided to pharmacies, government agencies and advocacy organizations. Excludes proprietary information from disclosure on department's website. Requires state-sponsored programs that use pharmacy benefit managers to use fee-only pharmacy benefit managers. Requires insurers to post specified information regarding formulary, tiers and costs to insurer's website. Requires 60-day advance notice to enrollees adversely affected by change in formulary. Requires insurer and allows pharmacy to notify insured that if cash price for drug is less than insured's cost-share for drug, insured may pay cash price and expense must be counted toward deductible or out-of-pocket maximum. Requires hospitals and other medical providers to disclose in patient billing information regarding mark-up on price of drug. Also requires billing to disclose price of drug charged to specified state agencies and insurers. Requires specified state agencies to report to Legislative Assembly on high-cost drugs. Requires Oregon Health Authority to refer to Pharmacy and Therapeutics Committee any drug exceeding specified cost. Requires patient advocacy organization with budget exceeding $50,000 that has registered lobbyist in this state to report to Oregon Government Ethics Commission and Oregon Health Authority specified information regarding funding received from participants in pharmaceutical supply chain. Requires pharmacy benefit managers to report to Department of Consumer and Business Services and plan sponsors specified information regarding rebates, reimbursements, fees and incentives paid for drugs by manufacturers, insurers and pharmacies. Requires drug advertisement to disclose wholesale price of drug.

Requires financial institution, when unilaterally closing account, to notify account holder of reason for closure.

Prohibits anyone other than patient from administering medication to end patient's life in humane and dignified manner. Defines "self-administer . " to include ingestion or other delivery method. ] Takes effect on 91st day following adjournment sine die.

Removes 10-day supply limitation on prescriptions for certain controlled substances issued by certified registered nurse anesthetists. Declares emergency, effective on passage.

Prohibits anyone other than patient from administering medication to end patient's life in humane and dignified manner. Defines "self-administer." Expands definition of "terminal disease." Permits patient to request medication to end patient's life in humane and dignified manner no earlier than 90 days after receiving terminal diagnosis. Creates exception to 90-day waiting period for patient with less than six months to live.

Removes requirement that person seeking intervention in juvenile dependency proceeding or rights of limited participation in juvenile dependency or delinquency proceeding prove that existing parties cannot adequately present case.

Directs Governor, with recommendations from Oregon Health and Science University Board of Directors, to appoint Rare Disease Ombudsman. Allows Rare Disease Ombudsman to solicit and accept gifts, grants and donations. Establishes Rare Disease Ombudsman Fund. Continuously appropriates moneys in fund to office of Rare Disease Ombudsman for certain purposes. Declares emergency, effective on passage.

Enacts Interstate Compact for Agreement Among the States to Elect the President by National Popular Vote.